BVAXF
Biovaxys Technology Corp

514
Mkt Cap
$5.41M
Volume
8,299.00
52W High
$0.4672
52W Low
$0.029
PE Ratio
-1.16
BVAXF Fundamentals
Price
$0.1855
Prev Close
$0.1829
Open
$0.1875
50D MA
$0.1749
Beta
-0.34
Avg. Volume
113,958.32
EPS (Annual)
-$0.1485
P/B
-2.05
Loading...
Loading...
News
all
press releases
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks·1mo ago
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks·1mo ago
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks·1mo ago
<
...
1
>

Latest BVAXF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.